We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Medical Sector has struggled year-to-date, declining nearly 16% and underperforming the S&P 500 in several timeframes, as the table below illustrates.
Image Source: Zacks Investment Research
One company residing in the sector, Ocugen (OCGN - Free Report) , is on deck to report quarterly results on Friday, August 5th, before the market opens.
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies that address rare and underserved eye diseases.
In addition, the company carries a Zacks Rank #5 (Strong Sell) with an overall VGM Score of an F. Right off the bat, that’s generally a pairing that you never want to see.
How does the company stack up heading into the print? Let’s find out.
Share Performance
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500. Shares broke off near early November 2021 and have been stuck in a deep downtrend.
Image Source: Zacks Investment Research
However, over the last three months, shares have tacked on 5.6% in value, outperforming the S&P 500 by a notable margin and indicating that buyers have started to come in.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish over the last 60 days, with one downwards estimate revision coming in. However, the Zacks Consensus EPS Estimate of -$0.08 reflects a rock-solid 38% uptick in quarterly earnings year-over-year.
Image Source: Zacks Investment Research
Quarterly Performance & Market Reactions
Ocugen has really struggled to report bottom-line results above expectations, missing the Zacks Consensus EPS Estimate in seven of its eight previous quarterly reports. In addition, the company recorded a massive 280% bottom-line miss in its latest quarter.
The market has reacted poorly to the company’s recent quarterly reports – shares have moved downwards twice following Ocugen’s last three quarterly reports.
Putting Everything Together
The company carries a Zacks Rank #5 (Strong Sell). In addition, shares have been stuck in a long-term downtrend, quarterly EPS has repeatedly been reported below expectations, but earnings are forecasted to grow by a double-digit percentage.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ocugen Q2 Preview: Rebound Quarter Inbound?
The Zacks Medical Sector has struggled year-to-date, declining nearly 16% and underperforming the S&P 500 in several timeframes, as the table below illustrates.
Image Source: Zacks Investment Research
One company residing in the sector, Ocugen (OCGN - Free Report) , is on deck to report quarterly results on Friday, August 5th, before the market opens.
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies that address rare and underserved eye diseases.
In addition, the company carries a Zacks Rank #5 (Strong Sell) with an overall VGM Score of an F. Right off the bat, that’s generally a pairing that you never want to see.
How does the company stack up heading into the print? Let’s find out.
Share Performance
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500. Shares broke off near early November 2021 and have been stuck in a deep downtrend.
Image Source: Zacks Investment Research
However, over the last three months, shares have tacked on 5.6% in value, outperforming the S&P 500 by a notable margin and indicating that buyers have started to come in.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish over the last 60 days, with one downwards estimate revision coming in. However, the Zacks Consensus EPS Estimate of -$0.08 reflects a rock-solid 38% uptick in quarterly earnings year-over-year.
Image Source: Zacks Investment Research
Quarterly Performance & Market Reactions
Ocugen has really struggled to report bottom-line results above expectations, missing the Zacks Consensus EPS Estimate in seven of its eight previous quarterly reports. In addition, the company recorded a massive 280% bottom-line miss in its latest quarter.
The market has reacted poorly to the company’s recent quarterly reports – shares have moved downwards twice following Ocugen’s last three quarterly reports.
Putting Everything Together
The company carries a Zacks Rank #5 (Strong Sell). In addition, shares have been stuck in a long-term downtrend, quarterly EPS has repeatedly been reported below expectations, but earnings are forecasted to grow by a double-digit percentage.